MNKDHIGH SIGNALFINANCIAL10-K

MannKind experienced a substantial deterioration in profitability with net income declining significantly while total liabilities increased materially.

The company's financial performance weakened considerably across multiple metrics, with profitability declining substantially despite maintaining revenue generation capabilities. The meaningful increase in total liabilities combined with reduced operating cash flow suggests potential financing pressures or operational challenges that warrant close investor scrutiny.

Comparing 2026-02-26 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

MannKind's financial position deteriorated notably during the period, with net income declining substantially from $27.6M to $5.9M while operating cash flow was meaningfully reduced. The company's cost structure expanded significantly, with SG&A expenses growing substantially and interest expense increasing to $15.2M, while total liabilities increased materially to $843.2M. Despite these pressures, the company maintained a stronger cash position at $74.9M and reduced capital expenditures, suggesting management is taking steps to preserve liquidity amid operational challenges.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-78.7%
$27.6M→$5.9M

Net income declined 78.7% — review whether driven by operations, interest costs, or non-recurring items.

Total Liabilities
Balance Sheet
+78.4%
$472.7M→$843.2M

Liabilities grew 78.4% — significant increase in debt or obligations, assess impact on financial flexibility.

Cash & Equivalents
Balance Sheet
+61.6%
$46.3M→$74.9M

Cash position surged 61.6% — strong cash generation or capital raise providing significant financial cushion.

Interest Expense
P&L
+58.6%
$9.6M→$15.2M

Interest expense surged 58.6% — significant debt increase or rising rates materially impacting earnings.

Operating Cash Flow
Cash Flow
-57.1%
$42.5M→$18.3M

Operating cash flow fell 57.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Capital Expenditure
Cash Flow
-52.9%
$9.7M→$4.6M

Capex reduced 52.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

SG&A Expense
P&L
+52.8%
$94.3M→$144.1M

SG&A up 52.8% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Operating Income
P&L
-46.5%
$72.6M→$38.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Stockholders Equity
Balance Sheet
+35.3%
-$78.8M→-$51.0M

Equity base grew 35.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Inventory
Balance Sheet
+26.6%
$27.9M→$35.3M

Inventory built 26.6% — monitor whether demand supports this build or if write-downs may follow.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-26
ADDED
As of February 13, 2026, there were 308,100,433 shares of the registrant s Common Stock outstanding.
Afrezza, Technosphere , BluHale , Dreamboat , Furoscix, Furoscix ReadyFlow, Cricket , V-Go and MannKind Corporation are our trademarks in the United States.
If United Therapeutics reduces its commercial emphasis on Tyvaso DPI, our revenues could decline materially.
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
Our products, product candidates and technology may not be able to compete effectively or may be rendered obsolete.
Changes in funding or staffing for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
The Blackstone Credit Facility contains restrictive covenants that may materially limit our operating flexibility.
A default under the instruments governing our indebtedness, including the Blackstone Credit Facility, could materially and adversely affect our financial position.
We may not realize the anticipated benefits of the scPharma acquisition or any future acquisition or strategic transaction; we may be unable to successfully integrate new products, technologies or businesses we acquire.
Healthcare legislation may impact the net sales of commercial products sold by us or any partner.
REMOVED
As of February 14, 2025, there were 303,591,344 shares of the registrant s Common Stock outstanding.
Afrezza, Technosphere , BluHale , Dreamboat , Cricket and V-Go, and MannKind Corporation are our trademarks in the United States.
Our products and product candidates may be rendered obsolete by rapid technological change.
We are a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
Our signature technologies Technosphere dry-powder formulations and Dreamboat inhalation devices offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
In our endocrine business unit, we currently commercialize two products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Afrezza was developed by us and received approval from the FDA in June 2014.
Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
We are solely responsible for the commercialization of Afrezza and V-Go in the United States.
( Biomm ), commenced commercialization of Afrezza in January 2020.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →